Pharma Aids Limited (DSE:PHARMAID)
Bangladesh · Delayed Price · Currency is BDT 505.60
-7.20 (-1.40%)
At close: Nov 12, 2026
Pharma Aids Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
| 507.39 | 438.09 | 421.23 | 308.49 | 323.05 | |
Revenue Growth | 15.82% | 4.00% | 36.55% | -4.50% | 15.25% |
Cost of Revenue | 345.46 | 306.09 | 291.88 | 257.2 | 219.58 |
Gross Profit | 161.93 | 131.99 | 129.36 | 51.29 | 103.47 |
Selling, General & Admin | 50.66 | 45.49 | 44.03 | 37.32 | 45.63 |
Other Operating Expenses | - | 0.14 | 0.07 | 2.21 | 1.94 |
Operating Expenses | 50.66 | 48.58 | 44.99 | 40.63 | 49.45 |
Operating Income | 111.27 | 83.41 | 84.36 | 10.66 | 54.02 |
Interest Expense | -2.51 | -1.75 | -0.26 | -0.24 | -0.38 |
Interest & Investment Income | - | 0.36 | 0.62 | - | - |
Other Non Operating Income (Expenses) | 0.41 | -0.07 | -0.16 | -0.13 | -0.09 |
EBT Excluding Unusual Items | 109.17 | 81.96 | 84.56 | 10.3 | 53.54 |
Gain (Loss) on Sale of Assets | - | 0.37 | - | - | - |
Pretax Income | 109.17 | 82.32 | 84.56 | 10.3 | 53.54 |
Income Tax Expense | 21.66 | 18.51 | 23.38 | 16.68 | 18.78 |
Net Income | 87.52 | 63.82 | 61.19 | -6.38 | 34.76 |
Net Income to Common | 87.52 | 63.82 | 61.19 | -6.38 | 34.76 |
Net Income Growth | 37.14% | 4.30% | - | - | -30.83% |
Shares Outstanding (Basic) | 3 | 3 | 3 | 3 | 3 |
Shares Outstanding (Diluted) | 3 | 3 | 3 | 3 | 3 |
Shares Change | - | - | - | - | - |
EPS (Basic) | 28.05 | 20.45 | 19.61 | -2.05 | 11.14 |
EPS (Diluted) | 28.05 | 20.45 | 19.61 | -2.05 | 11.14 |
EPS Growth | 37.14% | 4.30% | - | - | -30.83% |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | 56.2 | -17.37 | 22.6 | 5.06 | 29.15 |
Free Cash Flow Per Share | 18.01 | -5.57 | 7.25 | 1.62 | 9.34 |
Dividend Per Share | - | 3.000 | 2.500 | 1.000 | 5.000 |
Dividend Growth | - | 20.00% | 150.00% | -80.00% | 0% |
Gross Margin | 31.91% | 30.13% | 30.71% | 16.63% | 32.03% |
Operating Margin | 21.93% | 19.04% | 20.03% | 3.46% | 16.72% |
Profit Margin | 17.25% | 14.57% | 14.53% | -2.07% | 10.76% |
Free Cash Flow Margin | 11.08% | -3.97% | 5.37% | 1.64% | 9.02% |
EBITDA | 121.95 | 89.91 | 91.28 | 18.29 | 61.84 |
EBITDA Margin | 24.03% | 20.52% | 21.67% | 5.93% | 19.14% |
D&A For EBITDA | 10.68 | 6.5 | 6.92 | 7.62 | 7.82 |
EBIT | 111.27 | 83.41 | 84.36 | 10.66 | 54.02 |
EBIT Margin | 21.93% | 19.04% | 20.03% | 3.46% | 16.72% |
Effective Tax Rate | 19.84% | 22.48% | 27.64% | 161.99% | 35.07% |
Advertising Expenses | - | 0.61 | 0.75 | 0.89 | 0.97 |